1. Fachinformation Lynparza^® 100 mg/−150 mg Filmtabletten; aktueller Stand; Im Internet: Link; Stand: 14.03.2023
2. https://www.g-ba.de/downloads/92-975-4299/2020-11-30_Modul3A_Olaparib.pdf; Stand:
3. Clarke NW et al. New Engl J Med Evid 2022; 1(9) [Epub]
4. Clarke NW et al. J Clin Oncol 41, 2023 (suppl 6; abstr LBA16)
5. Lord CJ, Ashworth A. Science. 2017 Mar 17; 355(6330): 1152–1158
6. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun2017; 8:374. doi:10.1038/s41467-017-00393-y
7. Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov2012; 2:1134–1149. doi:10.1158/2159-8290.CD-12-0120
8. European Medicines Agency 2022, Lynparza; Im Internet: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lynparza-2; Stand: 21.12.2022
9. National Institutes of Health (NIH). Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. Im Internet: https:// clinicaltrials.gov/ct2/show/NCT03732820; Stand: 20.02.2023
10. Saad F et al. ESMO Congress 2022; Prasentation 1357
11. Saad F et al. J. Clin. Oncol. 40, no. 6_suppl (February 20, 2022) 11-11
12. Thiery-Vuillemin et al. J Clin Oncol 2022; [e-pub]; Im Internet: doi.org/10.1200/JCO.2022.40.16_suppl.5019; Stand: 21.12.2022
13. De Bono J et al. N Engl J Med 2020; 382(22): 2091–2102 und Supplementary Appendix
14. Hussain M et al. New Engl J Med 2020 Sep 20; 383(24): 2345–2357
15. Fachinformation ZYTIGA^®, aktuelle Version; Im Internet: Link; Stand: 
16. Fachinformation Prednison acis, aktuelle Version; Im Internet: Link; Stand: 

_{IB-Nummer DE-45934/22}